Cargando…
Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer
It has been reported that circulating tumor cells (CTCs) are beneficial for predicting tumor stage or treatment response. Although epithelial cell adhesion molecules (EpCAMs) and cytokeratin (CK) have been often used for the identification of CTCs, other tumor markers have not been fully investigate...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877362/ https://www.ncbi.nlm.nih.gov/pubmed/33381922 http://dx.doi.org/10.1002/cam4.3616 |
_version_ | 1783650151812825088 |
---|---|
author | Miki, Yuichiro Yashiro, Masakazu Kuroda, Kenji Okuno, Tomohisa Togano, Shingo Masuda, Go Kasashima, Hiroaki Ohira, Masaichi |
author_facet | Miki, Yuichiro Yashiro, Masakazu Kuroda, Kenji Okuno, Tomohisa Togano, Shingo Masuda, Go Kasashima, Hiroaki Ohira, Masaichi |
author_sort | Miki, Yuichiro |
collection | PubMed |
description | It has been reported that circulating tumor cells (CTCs) are beneficial for predicting tumor stage or treatment response. Although epithelial cell adhesion molecules (EpCAMs) and cytokeratin (CK) have been often used for the identification of CTCs, other tumor markers have not been fully investigated as detecting tools for CTCs. Thus, this study aims to clarify the significance of carcinoembryonic antigen (CEA, CD66e)‐positive CTCs in patients with gastric cancer. A total of 150 patients with gastric cancer were enrolled in this study. The mononuclear fraction of peripheral blood was enriched by Ficoll. The number of cells was enumerated depending on the positivity of EpCAM and CEA or CK by flow cytometry. The association of these cells with clinicopathologic characteristics was investigated. The mean age was 70 (range 28–92). The macroscopic type of gastric cancer was classified as 0/1/2/3/4/5 in 59/11/22/38/16/4 patients, respectively. Seventy‐one patients (47.3%) were diagnosed with intestinal‐type cancer, while 76 patients (50.7%) were diagnosed with the diffuse type. The mean numbers of cells with EpCAM−CK+, EpCAM+CK−, EpCAM+CK+, EpCAM−CEA+, EpCAM+CEA−, and EpCAM+CEA+ were 618, 237, 19.9, 1147, 291, and 7.41, respectively. The number of EpCAM−CEA+cells was significantly higher in patients with stage II–III and IV than in patients with stage I. The 3‐year RFS rate in patients with a high number of EpCAM−CEA+cells (>=622) was 57.5%, while it was 79.3% in patients with a low number of EpCAM−CEA+cells (<622) (log‐rank p = 0.0079). Thus, we conclude that CEA‐positive CTCs will be a clinically beneficial biomarker in patients with gastric cancer. |
format | Online Article Text |
id | pubmed-7877362 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78773622021-02-18 Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer Miki, Yuichiro Yashiro, Masakazu Kuroda, Kenji Okuno, Tomohisa Togano, Shingo Masuda, Go Kasashima, Hiroaki Ohira, Masaichi Cancer Med Clinical Cancer Research It has been reported that circulating tumor cells (CTCs) are beneficial for predicting tumor stage or treatment response. Although epithelial cell adhesion molecules (EpCAMs) and cytokeratin (CK) have been often used for the identification of CTCs, other tumor markers have not been fully investigated as detecting tools for CTCs. Thus, this study aims to clarify the significance of carcinoembryonic antigen (CEA, CD66e)‐positive CTCs in patients with gastric cancer. A total of 150 patients with gastric cancer were enrolled in this study. The mononuclear fraction of peripheral blood was enriched by Ficoll. The number of cells was enumerated depending on the positivity of EpCAM and CEA or CK by flow cytometry. The association of these cells with clinicopathologic characteristics was investigated. The mean age was 70 (range 28–92). The macroscopic type of gastric cancer was classified as 0/1/2/3/4/5 in 59/11/22/38/16/4 patients, respectively. Seventy‐one patients (47.3%) were diagnosed with intestinal‐type cancer, while 76 patients (50.7%) were diagnosed with the diffuse type. The mean numbers of cells with EpCAM−CK+, EpCAM+CK−, EpCAM+CK+, EpCAM−CEA+, EpCAM+CEA−, and EpCAM+CEA+ were 618, 237, 19.9, 1147, 291, and 7.41, respectively. The number of EpCAM−CEA+cells was significantly higher in patients with stage II–III and IV than in patients with stage I. The 3‐year RFS rate in patients with a high number of EpCAM−CEA+cells (>=622) was 57.5%, while it was 79.3% in patients with a low number of EpCAM−CEA+cells (<622) (log‐rank p = 0.0079). Thus, we conclude that CEA‐positive CTCs will be a clinically beneficial biomarker in patients with gastric cancer. John Wiley and Sons Inc. 2020-12-31 /pmc/articles/PMC7877362/ /pubmed/33381922 http://dx.doi.org/10.1002/cam4.3616 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Miki, Yuichiro Yashiro, Masakazu Kuroda, Kenji Okuno, Tomohisa Togano, Shingo Masuda, Go Kasashima, Hiroaki Ohira, Masaichi Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer |
title | Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer |
title_full | Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer |
title_fullStr | Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer |
title_full_unstemmed | Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer |
title_short | Circulating CEA‐positive and EpCAM‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer |
title_sort | circulating cea‐positive and epcam‐negative tumor cells might be a predictive biomarker for recurrence in patients with gastric cancer |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877362/ https://www.ncbi.nlm.nih.gov/pubmed/33381922 http://dx.doi.org/10.1002/cam4.3616 |
work_keys_str_mv | AT mikiyuichiro circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer AT yashiromasakazu circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer AT kurodakenji circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer AT okunotomohisa circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer AT toganoshingo circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer AT masudago circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer AT kasashimahiroaki circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer AT ohiramasaichi circulatingceapositiveandepcamnegativetumorcellsmightbeapredictivebiomarkerforrecurrenceinpatientswithgastriccancer |